Cargando…
New Therapeutic Options for Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC), one of the most common lethal diseases in the world, has a 5-year survival rate of only 7%. Hepatocellular carcinoma has no symptoms in the early stage but obvious symptoms in the late stage, leading to delayed diagnosis and reduced treatment efficacy. In recent years...
Autores principales: | Ma, Yu-Shui, Liu, Ji-Bin, Wu, Ting-Miao, Fu, Da |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791453/ https://www.ncbi.nlm.nih.gov/pubmed/32799550 http://dx.doi.org/10.1177/1073274820945975 |
Ejemplares similares
-
Hepatocellular Carcinoma—How to Determine Therapeutic Options
por: Mehta, Neil
Publicado: (2020) -
Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease
por: Cassese, Gianluca, et al.
Publicado: (2022) -
The role of ceRNA-mediated diagnosis and therapy in hepatocellular carcinoma
por: Shi, Yi, et al.
Publicado: (2021) -
Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options
por: Panneerselvam, Sugan, et al.
Publicado: (2023) -
ATG101-related signature predicts prognosis and therapeutic option in hepatocellular carcinoma
por: Wang, Bin, et al.
Publicado: (2022)